Sirna Therapeutics to Report First Quarter 2006 Financial Results on May 2, 2006
26 April 2006 - 10:08PM
PR Newswire (US)
Conference Call to Be Held at 4:30 p.m. EDT SAN FRANCISCO, April 26
/PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (NASDAQ:RNAI), a
leading RNAi therapeutics company, announced today that it will
release first quarter financial results for the period ended March
31, 2006 after the close of U.S. financial markets on Tuesday, May
2, 2006. Howard W. Robin, Sirna President and CEO, and the Sirna
senior management team will discuss progress to date in their
clinical and preclinical programs and provide an overview of
financial results during a conference call on Tuesday, May 2nd at
4:30 p.m. EDT (2:30 p.m. MDT; 1:30 p.m. PDT). A live audio webcast
of the call will be available at the Company's corporate web site
at http://www.sirna.com/. Participants are urged to log on to the
web site 15 minutes prior to the scheduled start time to download
and install any necessary audio software. To access the live
telephonic broadcast, domestic callers should dial (888) 802-2280;
international callers may dial (913) 312-1266. An audio webcast
replay will be available on Sirna's web site,
http://www.sirna.com/, for 60 days. Additionally, a telephonic
replay of the call will be maintained through midnight, Tuesday,
May 16, 2006. To access the replay, please dial (888) 203-1112 from
the U.S. or (719) 457-0820 when calling internationally, using
confirmation code 8556450. About Sirna Therapeutics Sirna
Therapeutics is a clinical-stage biotechnology company developing
RNAi-based therapies for serious diseases and conditions, including
age-related macular degeneration (AMD), hepatitis B and C,
dermatology, asthma, Huntington's disease, diabetes and oncology.
Sirna Therapeutics completed its Phase 1 clinical trial for
Sirna-027 in AMD in 2005 and with its strategic partner, Allergan,
Inc., expects to move Sirna-027 into Phase 2 clinical trials in
2006. Sirna has selected a clinical compound for hepatitis C virus,
Sirna-034, which the Company plans to bring into Phase 1 clinical
trials by the end of 2006. Sirna has established an exclusive
multi-year strategic alliance with GlaxoSmithKline for the
development of siRNA compounds for the treatment of respiratory
diseases. Sirna has a leading intellectual property portfolio in
RNAi covering over 250 mammalian gene and viral targets and over
175 issued or pending patents covering other major aspects of RNAi
technology. More information on Sirna Therapeutics is available on
the Company's web site at http://www.sirna.com/. Safe Harbor
Statement Statements in this press release which are not strictly
historical are "forward-looking" statements which should be
considered as subject to many risks and uncertainties. For example,
most drug candidates do not become approved drugs. The development
of Sirna-027 and Sirna-034 as well as Sirna's other programs are
still at a relatively early stage and subject to significant risks
and unknowns. Moreover, Sirna's ability to develop products and
operate as a going concern requires significant cash to fund its
operating programs. In addition, patent applications may not result
in issued patents, and issued patents may not be enforceable or
could be invalidated. Other risks and uncertainties include, among
others, Sirna's early stage of development and short operating
history, Sirna's history and expectation of losses and need to
raise capital, Sirna's need to obtain clinical validation and
regulatory approval for Sirna-027, Sirna-034 and Sirna's other
product candidates, any of which could have negative results,
Sirna's need to engage collaborators, Sirna's need to obtain and
protect intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including the Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Rebecca Galler
Robison Sirna Therapeutics, Inc. Senior Director, Corporate
Strategy (303) 449-6500 Investors Francesca DeMartino The Ruth
Group(646) 536-7024; DATASOURCE: Sirna Therapeutics, Inc. CONTACT:
Rebecca Galler Robison, Senior Director, Corporate Strategy of
Sirna Therapeutics, Inc., +1-303-449-6500; or Investors, Francesca
DeMartino of The Ruth Group, +1-646-536-7024, , for Sirna
Therapeutics, Inc. Web site: http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Sep 2023 to Sep 2024